AstraZeneca recently experienced positive developments, including the European approval of Calquence for mantle cell lymphoma and promising Phase III trial results for ENHERTU in breast cancer. These advances in oncology could add depth to the company's market performance. Meanwhile, broader market trends showed mixed movements, with the Dow Jones and S&P 500 rising, while Nasdaq slipped slightly. Despite a flat market overall last week due to investor anticipation of the Federal Reserve's interest rate decision, AstraZeneca's recent approvals and trial successes likely provided additional support to the company's steady market presence. We've identified 2 warning signs for AstraZeneca that you should be aware of.LSE:AZN Earnings Per Share Growth as at May 2025 The end of cancer? These 23 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. The European approval of Calquence and promising Phase III results for ENHERTU have the potential to support AstraZeneca's revenue and earnings growth. Over the past five years, the company achieved total returns, including share price and dividends, of 35.64%. This contrasts with its recent one-year underperformance compared to the UK Pharmaceuticals industry, which returned 9.6%. These developments could enhance the company's market share and product offering, though the competitive and regulatory landscapes present challenges. Analysts’ forecasts for AstraZeneca's future appear optimistic, projecting revenues to grow to $65.3 billion, with earnings rising to $13.5 billion by 2028. However, these outcomes depend on maintaining a PE ratio of 24.8x, lower than the current industry average. The stock currently trades at approximately £107.28, a 19.7% discount to the analyst price target of £133.57, suggesting potential for upward movement. Nonetheless, investors should weigh these factors against existing risks, including pricing pressures and biosimilar competition. Click here to discover the nuances of AstraZeneca with our detailed analytical financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Story Continues Companies discussed in this article include LSE:AZN. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected] View Comments
AstraZeneca (LSE:AZN) Reports Positive Phase 3 Trial Results For Breast Cancer Treatment
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...